RxDoctor Payments Data

Sagari Murali

Adult Health · Beacon, NYNPI 1053957902

Payments from drug & device makers

$1,841in general payments, 2019–2025

Across 52 payments — averaging $35.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$535
  • AstraZeneca$281
  • Aurinia Pharma U.S., Inc.$254
  • Bayer$230
  • Vifor Pharma, Inc.$149
  • OPKO Pharmaceuticals, LLC$79
  • plus $314 from 12 others

What the payments were for

  • Food & beverage$1,76396%
  • Education$794%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,841 in reported general payments places this provider in the 75th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$57,115
Medicare patients
234
Services billed
509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$25,089
TrulicityDulaglutide20$21,969
JardianceEmpagliflozin24$19,350
EliquisApixaban17$14,684
Praluent PenAlirocumab11$6,244
Albuterol Sulfate HfaAlbuterol Sulfate56$1,413
Levothyroxine Sodium132$1,298
Omeprazole77$1,203
Atorvastatin Calcium152$1,150
Rosuvastatin Calcium48$837
Lisinopril86$616
Gabapentin49$591
Metoprolol Succinate39$584
Levetiracetam12$583
Ezetimibe33$555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$25,08921 claims
Lilly USA, LLCTrulicity$19$21,96920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,828 adult health providers in New York.

Other adult health in Beacon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →